Assertio Holdings, Inc. 是一家商业制药公司,从事收购、许可和合并业务。公司总部位于伊利诺伊州的莱克福里斯特,目前拥有58名全职员工。该公司通过收购或许可已获批产品来构建其商业产品组合。其全面的商业能力包括通过销售团队和非人员推广模式进行市场营销,以及通过支付方合同和贸易分销进行市场准入。公司的主要上市产品包括:ROLVEDONTM(eflapegrastim-xnst)皮下使用注射剂、INDOCIN(吲哚美辛)栓剂、INDOCIN(吲哚美辛)口服混悬液、Sympazan(氯巴占)口腔膜、Otrexup(甲氨蝶呤)皮下注射剂、SPRIX(酮咯酸氨丁三醇)鼻喷雾剂、CAMBIA(双氯芬酸钾口服溶液)和Zipsor(双氯芬酸钾)液体填充胶囊。INDOCIN(吲哚美辛)栓剂和INDOCIN(吲哚美辛)口服混悬液产品属于非甾体抗炎药(NSAID)。
ASRT stock price ended at $0 on 星期日, after dropping NaN%
On the latest trading day Jul 05, 2026, the stock price of ASRT fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for ASRT decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.